• Martín Sívori, Ana Balanzat, Enrique Barimboim, Juan Pablo Casas, Luis Nannini, Ana Stok, and Santiago Vidaurreta.
• Unidad de Neumotisiología, Hospital Dr. J.M. Ramos Mejía y Centro Universitario de Neumonología, UBA, Buenos Aires, Argentina. E-mail: sivorimartin@yahoo.com.
• Medicina (B Aires). 2021 Jan 1; 81 Suppl 2: 1-32.

AbstractLast decades, a broad spectrum of inhaled devices (ID) had been developed to enhance efficacy and reduce adverse events. The correct use of IDs is a critical issue for controlling obstructive respiratory diseases. There is no recommendation on inhalation therapy in Argentina. This document aims to issue local recommendations about the prescription of IDs. Each device was reviewed regarding biophysical laws, indication, strength, limitations, correct technique of use, frequent mistakes, and device cleaning and maintenance. Nebulization should be restricted to drugs that are not available in other IDs (for example, for treatment of cystic fibrosis) or where other devices fail. Nebulization is not recommended during the SARS-CoV2 pandemic. A metered-dose inhaler must always be used with an aerochamber. Aerochambers reduce the incidence of adverse events and improve lung deposition. Metered-dose inhalers must be prescribed to patients who cannot generate a high inspiratory flow and dry powders to those who can generate an energetic inspiratory flow. We reviewed the use of different IDs in patients with cystic fibrosis and under mechanical ventilation. The individual choice of an ID will be based on several variables like clinical status, age, previous experience, patient preference, drug availability, and correct use of the device.

12 keywords...

hide…